C57BL/6N-Rnf10tm1b(KOMP)Wtsi/WtsiPh

Status

Under development - register interest

EMMA IDEM:14178
International strain nameC57BL/6N-Rnf10tm1b(KOMP)Wtsi/WtsiPh
Alternative nameEPD0025_2_A10
Strain typeTargeted Mutant Strains
Allele/Transgene symbolRnf10tm1b(KOMP)Wtsi,
Gene/Transgene symbolRnf10
DisclaimerPlease note that for EUCOMM and KOMP-CSD mice supplied to the scientific community by INFRAFRONTIER/EMMA:
  1. We can not guarantee a null mutation for Knock-out first alleles (tm1a alleles, see http://www.mousephenotype.org/about-ikmc/targeting-strategies) as the critical exon has not been deleted.
  2. That the structure of the targeted mutation in the ES cells obtained from EUCOMM/KOMP to generate EUCOMM/KOMP mice is not verified by INFRAFRONTIER/EMMA. It is recommended that the recipient confirms the mutation structure.
  3. No check for determining the copy number of the targeting construct in ES cells obtained from EUCOMM/KOMP is done by INFRAFRONTIER/EMMA.
  4. The level of quality control before mice are released is to confirm the individual mouse genotype by short range PCR.

Information from provider

Provider Wellcome Trust Sanger Institute
Provider affiliationWellcome Trust Sanger Institute
Genetic informationThis mouse line originates from KOMP ES clone EPD0025_2_A10. For further details on the construction of this clone see the page at the IMPC portal. The critical exon(s) were flanked by loxP sites, and subsequent cre expression excised this critical sequence resulting in a knockout reporter allele using a cell permeable HTN-Cre as described in doi:10.1007/s11248-013-9764-x. Click here for more information on KOMP final vectors.
Phenotypic informationPotential phenotyping data in the IMPC portal
ReferencesNone available

Information from EMMA

Archiving centreInstitute of Molecular Genetics, Prague, Czech Republic

Disease and phenotype information

IMPC phenotypes (allele matching)
  • decreased bone mineral density / IMPC
  • decreased circulating LDL cholesterol level / IMPC
  • decreased circulating HDL cholesterol level / IMPC
  • enlarged heart / IMPC
  • thin ventricular wall / IMPC
  • abnormal tibia morphology / IMPC
  • abnormal spleen morphology / IMPC
  • convulsive seizures / IMPC
  • decreased body length / IMPC
  • abnormal lens morphology / IMPC
  • cataract / IMPC
  • hyperactivity / IMPC
  • hypoactivity / IMPC
  • decreased startle reflex / IMPC
  • limb grasping / IMPC
  • increased vertical activity / IMPC
  • decreased circulating triglyceride level / IMPC
  • increased heart weight / IMPC
  • decreased hemoglobin content / IMPC
  • decreased circulating alkaline phosphatase level / IMPC
  • increased circulating chloride level / IMPC
  • abnormal bone structure / IMPC
  • increased lean body mass / IMPC
  • decreased lean body mass / IMPC
  • abnormal behavior / IMPC
  • decreased spleen weight / IMPC
  • decreased circulating cholesterol level / IMPC
  • improved glucose tolerance / IMPC
  • decreased circulating serum albumin level / IMPC
  • decreased cornea thickness / IMPC
  • increased circulating creatinine level / IMPC
  • decreased circulating creatinine level / IMPC
  • decreased circulating glucose level / IMPC
  • decreased circulating total protein level / IMPC
  • increased cardiac muscle contractility / IMPC
  • increased circulating sodium level / IMPC
  • decreased mean corpuscular hemoglobin concentration / IMPC
  • increased NK cell number / IMPC
  • decreased prepulse inhibition / IMPC
  • decreased total body fat amount / IMPC
  • decreased grip strength / IMPC
  • increased red blood cell distribution width / IMPC
  • increased bone mineral content / IMPC
  • decreased bone mineral content / IMPC
  • preweaning lethality, incomplete penetrance / IMPC
  • abnormal behavioral response to light / IMPC
  • abnormal sleep behavior / IMPC
  • increased fluid intake / IMPC
  • decreased total retina thickness / IMPC
  • increased or absent threshold for auditory brainstem response / IMPC
  • increased KLRG1-positive NK cell number / IMPC

Register interest

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

    Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

    * In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

    More details on pricing and delivery times

    Practical information

    Genotyping protocol

    Example health report
    (Current health report will be provided later)

    Material Transfer Agreement (MTA)
    Distribution of this strain is subject to a provider MTA. Both signing of the MTA and submission of the online EMMA Mutant Request Form are required before material can be shipped.

    EMMA conditions
    Legally binding conditions for the transfer

    Other EMMA strains

    Not found what you were looking for? Search here for other strains available from EMMA.


    Search
    INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).